Prudential Financial
CRSP icon

Prudential Financial’s CRISPR Therapeutics CRSP Stock Holding History

Prudential Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$815K Sell
14,945
-3,590
-19% -$189K ﹤0.01% 1735
2026
Q1 		$882K Buy
18,535
+8,955
+93% +$472K ﹤0.01% 1651
2025
Q4 		$502K Buy
9,580
+1,045
+12% +$62.6K ﹤0.01% 1829
2025
Q3 		$553K Buy
8,535
+3,525
+70% +$202K ﹤0.01% 1898
2025
Q2 		$237K Buy
+5,010
New +$194K ﹤0.01% 2162

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prudential Financial's CRSP Position: Q2 2026 in Review

Prudential Financial reduced its CRISPR Therapeutics (CRSP) stake by 19% in Q2 2026, selling an estimated $189K and leaving 14,945 shares worth $815K. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

Prudential Financial first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $882K in Q1 2026. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Prudential Financial held 14,945 shares of CRISPR Therapeutics worth $815K as of Q2 2026.
  • Prudential Financial sold 3,590 CRISPR Therapeutics shares in Q2 2026, an estimated $189K.
  • CRISPR Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1735 holding.
  • Prudential Financial first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Prudential Financial's CRISPR Therapeutics position peaked at $882K in Q1 2026.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.